目的 统计分析2019—2024年南京市第二医院抗结核药物使用情况及变化趋势，以期规范抗结核药物的合理应用。方法 对南京市第二医院2019—2024年26种抗结核药物销售金额、用药频度（DDDs）、限定日费用（DDC）及金额排序/ DDDs排序比（B/A）进行统计分析与评价。结果 2019—2024年，南京市第二医院抗结核药物销售金额先降后升，注射类销售金额2024年较2019年增长134.00%，其他口服类下降73.55%，莫西沙星针剂连续5年排名第1位。一线口服类DDDs值排序一直靠前，变化较大的有乙胺丁醇、阿米卡星及左氧氟沙星等。21种药物DDC呈下降趋势，8种药物DDC降幅大于75%。莫西沙星针剂、利福平针剂及利奈唑胺B/A远小于1；2019—2024年B/A≥1的药物平均占比在50%左右。8种免费抗结核药物于2024年消耗量占比均超过40%，免费环丝氨酸、氯法齐明及贝达喹啉占比均在80%左右。结论 南京市第二医院抗结核药物使用基本合理，政府免费药及“4＋7集中采购”药品的使用，使大部分药物DDC均有下降，从一定程度上缓解了患者经济负担，但存在用药不合理的现象，仍需加强监督管理，以期降低结核耐药风险。

Objective To investigate anti-tuberculosis drugs usage in The Second Hospital of Nanjing from 2019 to 2024 and analyze its change trend, in order to regulate its rational application. Methods The annual consumption sums, DDDs, DDC and the B/A of anti-tuberculosis drugs in The Second Hospital of Nanjing from 2019 to 2024 were obtained and analyzed. Results From 2019 to 2024, the annual consumption sums of anti-tuberculosis drugs firstly decreased then increased, and consumption sums of injection drugs increased by 134.00% in 2024 compared with 2019, while the other oral drugs decreased by 73.55%. Moxifloxacin for injection ranked top 1 for five consecutive years. The ranks of DDDs of ethambutol, amikacin, and levofloxacin changed markedly and the top ones were always first-line oral anti-tuberculosis drugs. DDC of 21 drugs appeared downtrend, especially 8 drugs declined by more than 75%. The B/A of moxifloxacin for injection, rifampicin for injection, and linezolid tablets were much less than 1, and drugs with B/A≥1 accounted for 50% from 2019 to 2024. In 2024, consume proportions of 8 kinds of free anti-tuberculosis drugs were more than 40%, and among which free cycloserine, clofazimine, and bedaquiline accounted for 80%. Conclusion The application of anti-tuberculosis drugs in The Second Hospital of Nanjing was basically reasonable, and because of the application of free anti-tuberculosis drugs from government and the “4＋7” procurement with quantity, DDC of most of anti-tuberculosis drugs has decreased which could be helpful to relieve economic pressure of patients. Unreasonable applications of anti-tuberculosis drugs still existed, so supervision and management should be strengthened in order to reduce the risk of anti-tuberculosis drugs resistance.

R978.3